MİKROBİYOTANIN HASTALIKLAR ÜZERİNDEKİ ETKİSİ

Yıl 2021, Cilt: 45 Sayı: 1, 96 - 108, 18.01.2021

Betül Çakmak , Bahar İnkaya

https://doi.org/10.33483/jfpau.808595

Cited By: 2

Öz

Amaç: Vücudumuzda yaşayan mikroorganizmalar olarak tanımlanan mikrobiyata kavramı günümüzde oldukça populerdir. Son yıllarda gerçekleştirilen araştırmalarla birlikte yeni bir organ olarak tanımlanmaktadır. Bu derlemenin yazılmasındaki amaç, insan vücudu açısından oldukça önemli fonksiyon ve etkileri bulunan mikrobiyotanın kronik hastalıklara yönelik etkisini değerlendirmektir.

Sonuç ve Tartışma: Her bireye özgü olarak farklı özellikler gösteren mikrobiyatanın kronik hastalıkların gelişiminde etkileri bulunmaktadır. Özellikle hipertansiyon, diyabet, kanser, inflamatuvar bağırsak hastalığı, alzheirmer, parkinson bu hastalıklara örnek olarak verilebilir. Bu sebeple sağlıklı Mikrobiyata aktivitesinin sürdürülmesi ve geliştirilmesi oldukça önemlidir. Özellikle riskli grup olarak tanımlanan bireyler ve kronik hastalığı olanlar çerçevesinde eğitimlerin planlanması, doğru sağlık davranışı yönlendirilmelerin yapılması ve desteklenmesinin bu sürece katkı sağlayacağı düşünülmektedir.

Anahtar Kelimeler

Hastalık, mikrobiyota, sağlık

THE EFFECT OF MICROBIOTA ON DISEASES

Öz

Objective: The concept of microbiota, which is defined as microorganisms living in our bodies, is quite popular today. It is defined as a new organ with the researches carried out in recent years. The purpose of writing this review is to evaluate the effect of microbiota, which has very important functions and effects for the human body, on chronic diseases.

Result and Discussion: Microbiota, which has different characteristics specific to each individual, has effects on the development of chronic diseases. Especially hypertension, diabetes, cancer, inflammatory bowel disease, Alzheimer's, Parkinson can be given as examples of these diseases. For this reason, it is very important to maintain and develop healthy Microbiota activity. It is thought that planning trainings, directing and supporting correct health behaviors within the framework of individuals defined as a risky group and those with chronic diseases will contribute to this process.

Anahtar Kelimeler

Disease, health, microbiota

Kaynakça

• Lederberg, J., McCray, A. T. (2001). Ome SweetOmics--A genealogical treasury of words. The scientist, 15(7), 8-8.
• Yılmaz, K., Altındiş, M. (2017). Sindirim sistemi mikrobiyotasi ve fekal transplantasyon. Nobel Medicus, 13(1), 9-15.
• Altındiş, S., Adıgül, M. P. (2017). Mikrobiyota Çalışmalarında Etik. SDÜ Sağlık Bilimleri Dergisi, 8(3), 62-68.
• Varım, P., Vatan, M. B.,Varım, C. (2017). Kardiyovasküler Hastalıklar ve Mikrobiyota. Journal of Biotechnology and Strategic Health Research, 1, 141-147.
• Karatay, E. Mikrobiyota, prebiyotik ve probiyotikler. Anadolu Güncel Tıp Dergisi, 1(3), 68-71.
• Özdemir, A., & Demirel, Z. B. (2017). Beslenme ve Mikrobiyota ilişkisi. Journal of Biotechnology and Strategic Health Research, 1, 25-33.
• Ficara, M., Pietrella, E., Spada, C., Della Casa Muttini, E., Lucaccioni, L., Iughetti, L., Berardi, A. (2020). Changes of intestinal microbiota in early life. The Journal of Maternal-Fetal & Neonatal Medicine, 33(6), 1036-1043.
• Pelzer, E., Gomez-Arango, L. F., Barrett, H. L., Nitert, M. D. (2017). Maternal health and the placental microbiome. Placenta, 54, 30-37.
• Matamoros, S., Gras-Leguen, C., Le Vacon, F., Potel, G., de La Cochetiere, M. F. (2013). Development of intestinal microbiota in infants and its impact on health. Trends in microbiology, 21(4), 167-173.
• Ballard, O., Morrow, A. L. (2013). Human milk composition: nutrients and bioactive factors. Pediatric Clinics, 60(1), 49-74.
• Madan, J. C., Hoen, A. G., Lundgren, S. N., Farzan, S. F., Cottingham, K. L., Morrison, H. G., Sogin, M.L., Li, H., Moore, J.H., Karagas, M. R. (2016). Association of cesarean delivery and formula supplementation with the intestinal microbiome of 6-week-old infants. JAMA pediatrics, 170(3), 212-219.
• Laursen, M. F., Bahl, M. I., Michaelsen, K. F., Licht, T. R. (2017). First foods and gut microbes. Frontiers in microbiology, 8, 356.
• De Filippo, C., Cavalieri, D., Di Paola, M., Ramazzotti, M., Poullet, J. B., Massart, S., Collini, S., Pieraccini, G., Lionetti, P. (2010). Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proceedings of the National Academy of Sciences, 107(33), 14691-14696.
• Ayyıldız, F.,Yıldıran, H. (2019). Farklı Diyet Modellerinin Bağırsak Mikrobiyotası Üzerine Etkisi. Beslenme ve Diyet Dergisi, 47(2), 77-86.
• Singh, R. K., Chang, H. W., Yan, D., Lee, K. M., Ucmak, D., Wong, K., Abrouk, M., Farahnik, B., Nakamura, M., Zhu, T.H., Bhutani, T. (2017). Influence of diet on the gut microbiome and implications for human health. Journal of translational medicine, 15(1), 73.
• Wu, G. D., Compher, C., Chen, E. Z., Smith, S. A., Shah, R. D., Bittinger, K., Chehoud, C., Alberberg, L.G., Nessel, L., Gilroy, E., Star, J. (2016). Comparative metabolomics in vegans and omnivores reveal constraints on diet-dependent gut microbiota metabolite production. Gut, 65(1), 63-72.
• Melini, V., Melini, F. (2019). Gluten-free diet: Gaps and needs for a healthier diet. Nutrients, 11(1), 170.
• Altuntas, Y., Batman, A. (2017). Mikrobiyota ve metabolik sendrom. Turk Kardiyol Dern Ars, 45(3), 286-296.
• Kim, D. H. (2015). Gut microbiota-mediated drug-antibiotic interactions. Drug Metabolism and Disposition, 43(10), 1581-1589.
• Bäckhed, F., Manchester, J. K., Semenkovich, C. F., Gordon, J. I. (2007). Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proceedings of the National Academy of Sciences, 104(3), 979-984. Kalip, K., Atak, N. Intestinal microbiota and health. Türkiye Halk Sağlığı Dergisi, 16(1), 58-73.
• de Cossío, L. F., Fourrier, C., Sauvant, J., Everard, A., Capuron, L., Cani, P. D., Laye, S., Castanon, N. (2017). Impact of prebiotics on metabolic and behavioral alterations in a mouse model of metabolic syndrome. Brain, behavior, and immunity, 64, 33-49.
• Obezite tanı ve tedavi kılavuzu -Türkiye Endokrinoloji ve Metabolizma Derneği - ISBN 978-605-4011-31-5 8. Baskı: Nisan 2019.
• Clarke, S. F., Murphy, E. F., O'Sullivan, O., Lucey, A. J., Humphreys, M., Hogan, A., Hayes, P., O’Reilly, M., Jeffery, I.B., Wood-Martin, R., Kerins, D. M. (2014). Exercise and associated dietary extremes impact on gut microbial diversity. Gut, 63(12), 1913-1920.
• Kadooka, Y., Sato, M., Ogawa, A., Miyoshi, M., Uenishi, H., Ogawa, H., Ikuyama, K., Kagoshima, M., Tsuchida, T. (2013). Effect of Lactobacillus gasseri SBT2055 in fermented milk on abdominal adiposity in adults in a randomised controlled trial. British Journal of Nutrition, 110(9), 1696-1703.
• Rodes, L., Khan, A., Paul, A., Coussa-Charley, M., Marinescu, D., Tomaro-Duchesneau, C., Shao, W., Kahouli, I., Prakash, S. (2013). Effect of probiotics Lactobacillus and Bifidobacterium on gut-derived lipopolysaccharides and inflammatory cytokines: an in vitro study using a human colonic microbiota model. J Microbiol Biotechnol, 23(4), 518-526.
• Seldin, M. M., Meng, Y., Qi, H., Zhu, W., Wang, Z., Hazen, S. L., Lusis, A. J., Shih, D. M. (2016). Trimethylamine N‐oxide promotes vascular inflammation through signaling of mitogen‐activated protein kinase and nuclear factor‐κB. Journal of the American Heart Association, 5(2), e002767
• Kozarov, E. V., Dorn, B. R., Shelburne, C. E., Dunn Jr, W. A., Progulske-Fox, A. (2005). Human atherosclerotic plaque contains viable invasive Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis. Arteriosclerosis, thrombosis, and vascular biology, 25(3), e17-e18.
• Gibson Iii, F. C., Hong, C., Chou, H. H., Yumoto, H., Chen, J., Lien, E., Wong, J., Attardo Genco, C. (2004). Innate immune recognition of invasive bacteria accelerates atherosclerosis in apolipoprotein E-deficient mice. Circulation, 109(22), 2801-2806.
• Eminler, A. T., Toka, B., Uslan, M. İ. (2017). İnflamatuar Barsak Hastalığı Ve Barsak Mikrobiyotası. Journal of Biotechnology and Strategic Health Research, 1, 81-85.
• Sokol, H., Pigneur, B., Watterlot, L., Lakhdari, O., Bermúdez-Humarán, L. G., Gratadoux, J. J., Blugeon, S., Bridonneau, C., Furet, J.P., Corthier, G., Grangette, C., Vasquez, N., Pochart, P., Trugnan, G., Thomas, G., Blottiere, H.M., Dore, J., Marteau, P., Seksik, P., Langella, P. (2008). Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proceedings of the National Academy of Sciences, 105(43), 16731-16736.
• Özden, G., Aktura, S. Ç., & Sarıtaş, S. Ç. (2020). Fekal Mikrobiyota Transplantasyonu ve Hemşirelik Bakımı. Hacettepe Üniversitesi Hemşirelik Fakültesi Dergisi, 7(2), 175-179.
• Friedland, R. P. (2015). Mechanisms of molecular mimicry involving the microbiota in neurodegeneration. Journal of Alzheimer's Disease, 45(2), 349-362.
• Bravo, J. A., Forsythe, P., Chew, M. V., Escaravage, E., Savignac, H. M., Dinan, T. G., Bienenstock, J., Cryan, J. F. (2011). Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proceedings of the National Academy of Sciences, 108(38), 16050-16055.
• Alagöz, A. N. (2017). Mikrobiyota ve nörodejenerasyon. Journal of Biotechnology and Strategic Health Research, 1, 115-122.
• Zhu, X., Raina, A. K., Lee, H. G., Casadesus, G., Smith, M. A., Perry, G. (2004). Oxidative stress signalling in Alzheimer's disease. Brain research, 1000(1-2), 32-39.
• Altun, H. K., Yıldız, E. A. (2018). Diyabet ve Mikrobiyota. Türkiye Klinikleri Beslenme ve Diyetetik-Özel Konular, 4(2), 36-42.
• Yetkin, İ., Yetiş, H., Satış, N. K. (2017). Bağırsak mikrobiyotasının insülin direnci, diabetes mellitus ve obezite ile ilişkisi. Türkiye Diyabet ve Obezite Dergisi, 2(1), 1-8
• Qin, J., Li, Y., Cai, Z., Li, S., Zhu, J., Zhang, F., Liang, S., Zhang, W., Guan, Y., Shen, D., Peng, Y., Zhang, D., Jie, Z., Wu, W., Qin, Y., Xue, W., Li, J., Han, L., Lu, D., Wu, P., Dai, Y., Sun, X., Li, Z., Tang, A., Zhong, S., Li, X., Chen, W., Xu, R., Wang, M., Feng, Q., Gong, M., Jing, Y., Zhang, Y., Zhang, M., Hansen, T., Sanchez, G., Raes, J., et al. (2012). A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature, 490(7418), 55-60.
• Karlsson, F. H., Tremaroli, V., Nookaew, I., Bergström, G., Behre, C. J., Fagerberg, B., Nielsen, J., Bäckhed, F. (2013). Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature, 498(7452), 99-103.
• Raza, M. H., Gul, K., Arshad, A., Riaz, N., Waheed, U., Rauf, A., Aldakheel, F., Alduraywish, S., Ur Rehman, M., Abdullah, M., Arshad, M. (2019). Microbiota in cancer development and treatment. Journal of Cancer Research and Clinical Oncology, 145(1), 49-63.
• Salman, T., Varol, U., Yıldız, İ., Küçükzeybek, Y., Alacacıoğlu, A. (2015). Mikrobiyota ve kanser. Acta Oncologica Turcica, 48(2), 73-78.
• Perez-Chanona, E., Trinchieri, G. (2016). The role of microbiota in cancer therapy. Current opinion in immunology, 39, 75-81.
• Karpiński, T. M. (2019). Role of oral microbiota in cancer development. Microorganisms, 7(1), 20.
• Fan, X., Alekseyenko, A. V., Wu, J., Peters, B. A., Jacobs, E. J., Gapstur, S. M., Purdue, M.P., Abnet, C.C., Stolzenberg-Solomon, R., Miller, G., Ravel, J. (2018). Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study. Gut, 67(1), 120-127.
• Genç, A. C., HacIbekiroğlu, İ. (2017). Mikrobiyota ve Kanser. Journal of biotechnology and strategic health research, 1, 123-131.
• Yip, L. Y., Chan, E. C. Y. (2015). Investigation of host–gut microbiota modulation of therapeutic outcome. Drug Metabolism and Disposition, 43(10), 1619-1631.
• Ottman, N., Smidt, H., De Vos, W. M., Belzer, C. (2012). The function of our microbiota: who is out there and what do they do?. Frontiers in cellular and infection microbiology, 2, 104.
• Karadsheh, Z., Sule, S. (2013). Fecal transplantation for the treatment of recurrent clostridium difficile infection. North American journal of medical sciences, 5(6), 339.